- Issuer
- L&G
- Inception Date
- Jan 18, 2018
- Region
- Global (Broad)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- Solactive Pharma Breakthrough Value Index Net Total Return
- Domicile
- Ireland
- Distribution Policy
- Accumulating
- Asset Class
- Equity
- Asset Class Size
- Small-Cap
- Asset Class Style
- Growth
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BIOT.L Performance Chart
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) is up 8.3% since the beginning of the year. BIOT.L is currently trading at $15 per share. Investors who bought $1,000 worth of BIOT.L shares 5 years ago would now be looking at an investment worth $1,150.
Loading charts...
Returns By Period
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) has returned 8.27% so far this year and 33.81% over the past 12 months.
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF
- 1D
- 0.31%
- 1M
- 7.79%
- 6M
- 7.56%
- YTD
- 8.27%
- 1Y
- 33.81%
- 3Y*
- 10.20%
- 5Y*
- 2.83%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.38%
- 1M
- 0.24%
- 6M
- 9.32%
- YTD
- 10.62%
- 1Y
- 21.28%
- 3Y*
- 18.90%
- 5Y*
- 11.84%
- 10Y*
- 13.36%
BIOT.L Monthly Returns History
Based on dividend-adjusted daily data since Jan 18, 2018, BIOT.L's average daily return is +0.03%, while the average monthly return is +0.51%. At this rate, an investment would double in approximately 11.4 years.
Historically, 58% of months were positive and 42% were negative. The best month was Apr 2020 with a return of +17.3%, while the worst month was Oct 2018 at -14.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.
On a daily basis, BIOT.L closed higher 48% of trading days. The best single day was Jul 20, 2018 with a return of +8.1%, while the worst single day was Apr 9, 2025 at -5.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.15% | 1.91% | -3.45% | 3.06% | -0.36% | 8.64% | -1.50% | 8.27% | |||||
| 2025 | 4.61% | 4.12% | -3.04% | 0.09% | 0.76% | -0.56% | 6.72% | 5.50% | 5.46% | 5.50% | 4.91% | -1.94% | 36.47% |
| 2024 | -5.41% | -1.20% | 0.30% | -5.87% | 3.23% | 2.29% | 6.31% | 6.13% | -2.89% | -0.65% | 0.28% | -6.90% | -5.31% |
| 2023 | 4.46% | -4.91% | -2.77% | 3.25% | -4.44% | -2.18% | 3.32% | -2.06% | -6.20% | -7.98% | 7.29% | 3.84% | -9.28% |
| 2022 | -7.77% | 0.95% | 1.83% | -5.37% | -4.96% | 1.29% | 1.60% | -3.10% | -2.82% | 2.22% | 7.10% | 1.25% | -8.41% |
| 2021 | 0.11% | -3.74% | -2.44% | 1.84% | 0.12% | 4.98% | -3.01% | 3.36% | -2.98% | 0.04% | -3.92% | 2.46% | -3.60% |
Benchmark Metrics
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF has an annualized alpha of 1.10%, beta of 0.36, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since January 18, 2018.
- This ETF participated in 78.50% of S&P 500 Index downside but only 53.78% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.36 may look defensive, but with R2 of 0.12 this ETF is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
- R2 of 0.12 means this ETF moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1.10%
- Beta
- 0.36
- R²
- 0.12
- Upside Capture
- 53.78%
- Downside Capture
- 78.50%
Expense Ratio
BIOT.L has an expense ratio of 0.49%, placing it in the medium range.
Return for Risk
Risk / Return Rank
BIOT.L ranks 67 for risk / return — better than 67% of ETFs on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIOT.L | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.04 | ||
| Sortino ratioReturn per unit of downside risk | +0.04 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.31 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 3.52 | 2.35 | +1.17 |
| Martin ratioReturn relative to average drawdown | 10.12 | 10.19 | -0.07 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF was 34.44%, occurring on Apr 9, 2025. Recovery took 152 trading sessions.
The current L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF drawdown is 5.72%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-34.44%Apr 2025 | 4y 1mo | 7mo 9d | 4y 9moFeb 2021 - Nov 2025 | 2025 selloff2025 |
-27.13%Mar 2020 | 28d | 1mo 5d | 2mo 3dFeb 2020 - Apr 2020 | COVID crash2020 |
-23.58%Dec 2018 | 2mo 23d | 1y 1mo | 1y 4moOct 2018 - Feb 2020 | Rate-hike selloffLate 2018 |
-10.88%Apr 2018 | 2mo 7d | 3mo 15d | 5mo 22dJan 2018 - Jul 2018 | — |
-9.55%Mar 2026 | 2mo 11d | 21d | 3mo 2dJan 2026 - Apr 2026 | — |
Drawdown Indicators
| BIOT.L | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.44% | -56.78% | +22.34% |
Max Drawdown (1Y)Largest decline over 1 year | -9.55% | -9.10% | -0.45% |
Max Drawdown (3Y)Largest decline over 3 years | -19.91% | -18.90% | -1.01% |
Max Drawdown (5Y)Largest decline over 5 years | -33.80% | -25.43% | -8.37% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -5.72% | -0.49% | -5.23% |
Average DrawdownAverage peak-to-trough decline | -13.31% | -10.70% | -2.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.33% | 2.09% | +1.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with BIOT.L
Add L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BIOT.L